This study sought to assess the role of peripheral blood VEGF and some inflammation biomarkers in evaluating clinical response and prognosis in patients with non-operative esophageal squamous cell carcinoma (ESCC). This evidence concerns the gene VEGFA and esophageal squamous cell carcinoma.